| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.47 |
| 52 Week High | CN¥26.98 |
| 52 Week Low | CN¥13.63 |
| Beta | 1.04 |
| 11 Month Change | 6.47% |
| 3 Month Change | 3.90% |
| 1 Year Change | -32.97% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301211 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 11.1% | 13.8% | 15.4% |
| 1Y | -33.0% | -10.4% | -7.9% |
Return vs Industry: 301211 underperformed the CN Pharmaceuticals industry which returned -10.4% over the past year.
Return vs Market: 301211 underperformed the CN Market which returned -7.9% over the past year.
Price Volatility
| 301211 volatility | |
|---|---|
| 301211 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.5% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 301211 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301211's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,012 | Qun Liang | www.biocause.com |
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Fundamentals Summary
| 301211 fundamental statistics | |
|---|---|
| Market cap | CN¥4.46b |
| Earnings (TTM) | CN¥131.57m |
| Revenue (TTM) | CN¥499.13m |
33.9x
P/E Ratio8.9x
P/S RatioIs 301211 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301211 income statement (TTM) | |
|---|---|
| Revenue | CN¥499.13m |
| Cost of Revenue | CN¥306.11m |
| Gross Profit | CN¥193.02m |
| Other Expenses | CN¥61.45m |
| Earnings | CN¥131.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 38.67% |
| Net Profit Margin | 26.36% |
| Debt/Equity Ratio | 0% |
How did 301211 perform over the long term?
See historical performance and comparison